Oramed Pharmaceuticals : FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Rabinowitz Michael

FORM 4	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Check this box if no	Washington, D.C. 20549
longer subject to
Section 16. Form 4 or

Form 5 obligations may STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
continue. See	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the
Instruction 1(b).

Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours
per response...	0.5

1. Name and Address of Reporting Person

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

Rabinowitz

Michael

Oramed Pharmaceuticals Inc. [ORMP]

____

(Check all applicable)

Director

____

10% Owner

(Last)

(First)

(Middle)

3. Date of Earliest Transaction (Month/Day/Year)

XOfficer (give title below)____

Other (specify below)

1185 Avenue of the Americas

01/03/2023

Chief Commercial Officer

(Street)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

New York

NY

10036

XForm filed by One Reporting Person

____

Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security

2. Transaction

2A. Deemed

3. Transaction

4. Securities Acquired (A) or

5. Amount of Securities

6.

7. Nature of

(Instr. 3)

Date

Execution Date, if

Code

Disposed of (D)

Beneficially Owned Following

Ownership

Indirect

(Month/Day/Year)

any

(Instr. 8)

(Instr. 3, 4 and 5)

Reported Transaction(s)

Form:

Beneficial

(Month/Day/Year)

(Instr. 3 and 4)

Direct (D)

Ownership

or Indirect

(Instr. 4)

(A) or

(I)

Code

V

Amount

(D)

Price

(Instr. 4)

Common Stock

01/03/2023 (1)

S

1,425

D

$13.0132

138,043

D

Common Stock

01/03/2023 (1)

S

11,900

D

$12.4917

126,143

D

(2)

Page 1 of 2.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction	3A. Deemed	4.		5. Number	6. Date Exercisable and	7. Title and
Derivative	Conversion	Date	Execution Date, if	Transaction	of	Expiration Date	Amount of
Security	or Exercise	(Month/Day/Year)	any	Code	Derivative	(Month/Day/Year)	Underlying
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Securities			Securities
	Derivative					Acquired			(Instr. 3 and 4)
	Security					(A) or
						Disposed of
						(D)
						(Instr. 3, 4,
						and 5)
											Amount
											or
								Date	Expiration		Number
				Code	V	(A)	(D)	Exercisable	Date	Title	of Shares

8. Price of	9. Number of	10.	11. Nature
Derivative	Derivative	Ownership	of Indirect
Security	Securities	Form of	Beneficial
(Instr. 5)	Beneficially	Derivative	Ownership
	Owned	Security:	(Instr. 4)
	Following	Direct (D)
	Reported	or Indirect
	Transaction(s)	(I)
	(Instr. 4)	(Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $13.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the above range.

/s/ Michael Rabinowitz	01/04/2023
**Signature of Reporting Person		Date

• If the form is filed by more than one reporting person, see Instruction 4(b)(v).

• Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
  Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Page 2 of 2.